Costs, length of stay, and mortality of super-refractory status epilepticus: A population-based study from Germany.
Adam StrzelczykSonja AnsorgeJana HapfelmeierVijayveer BonthapallyM Haim ErderFelix RosenowPublished in: Epilepsia (2017)
This study evaluated the hospital treatment costs associated with admissions classified by the algorithm as SRSE in Germany. SRSE represented 13% of all SE admissions, but resulted in 56% of all SE-related costs. The lack of approved treatments and limited number of evidence-based treatment guidelines highlight the need for further evaluations of the SRSE burden of illness and the potential for further optimization of treatments for SRSE.